Nothing Special   »   [go: up one dir, main page]

CR10619A - Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos - Google Patents

Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos

Info

Publication number
CR10619A
CR10619A CR10619A CR10619A CR10619A CR 10619 A CR10619 A CR 10619A CR 10619 A CR10619 A CR 10619A CR 10619 A CR10619 A CR 10619A CR 10619 A CR10619 A CR 10619A
Authority
CR
Costa Rica
Prior art keywords
mimeticbodies
peptide
compositions
methods
similar
Prior art date
Application number
CR10619A
Other languages
English (en)
Inventor
Neil Karyn T O
Kristen Picha
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CR10619A publication Critical patent/CR10619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
CR10619A 2006-07-18 2009-02-18 Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos CR10619A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83170406P 2006-07-18 2006-07-18

Publications (1)

Publication Number Publication Date
CR10619A true CR10619A (es) 2009-06-04

Family

ID=38596585

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10619A CR10619A (es) 2006-07-18 2009-02-18 Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos

Country Status (18)

Country Link
US (2) US20090325873A1 (es)
EP (1) EP2049567A2 (es)
JP (1) JP2010500868A (es)
KR (1) KR20090039787A (es)
CN (1) CN101535341A (es)
AR (1) AR061930A1 (es)
AU (1) AU2007275294A1 (es)
BR (1) BRPI0714334A2 (es)
CA (1) CA2658286A1 (es)
CR (1) CR10619A (es)
EA (1) EA200970131A1 (es)
EC (1) ECSP099079A (es)
MX (1) MX2009000748A (es)
NO (1) NO20090780L (es)
TW (1) TW200821386A (es)
UY (1) UY30494A1 (es)
WO (1) WO2008011446A2 (es)
ZA (1) ZA200901132B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
KR101574814B1 (ko) 2007-11-02 2015-12-04 노파르티스 아게 개선된 ｎｏｇｏ-ａ 결합 분자 및 이의 제약적 용도
CN102083854A (zh) * 2008-06-17 2011-06-01 大塚化学株式会社 附加了糖链的glp-1肽
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2429503A1 (en) * 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
US8455533B2 (en) 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP5908888B2 (ja) 2010-04-16 2016-04-26 ヤンセン バイオテツク，インコーポレーテツド 改変された植物のシステインプロテアーゼ及びその使用
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
CN103204944B (zh) * 2013-03-26 2014-05-28 江苏健德生物药业有限公司 用于治疗糖尿病的长效免疫融合蛋白
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2019036859A1 (zh) * 2017-08-21 2019-02-28 中国科学院动物研究所 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途
SG11202000940XA (en) 2017-08-24 2020-02-27 Novo Nordisk As Glp-1 compositions and uses thereof
TWI639987B (zh) * 2017-10-11 2018-11-01 奇美醫療財團法人奇美醫院 具有位置感知的穿刺輔助教學裝置
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113226351A (zh) * 2018-10-22 2021-08-06 詹森药业有限公司 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
US6849719B2 (en) * 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
JP2000319297A (ja) * 1999-03-30 2000-11-21 Noguchi Inst 酵素的に安定な複合糖ペプチドの調製法
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
DE60139430D1 (de) * 2000-12-07 2009-09-10 Lilly Co Eli GLP-1 Fusionsproteine
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7241733B2 (en) * 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
CA2502118A1 (en) 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
CA2563379A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
JP2010500868A (ja) 2010-01-14
TW200821386A (en) 2008-05-16
CA2658286A1 (en) 2008-01-24
US20080044411A1 (en) 2008-02-21
BRPI0714334A2 (pt) 2013-05-14
EA200970131A1 (ru) 2009-08-28
NO20090780L (no) 2009-04-03
CN101535341A (zh) 2009-09-16
UY30494A1 (es) 2008-01-31
ECSP099079A (es) 2009-02-27
KR20090039787A (ko) 2009-04-22
AU2007275294A1 (en) 2008-01-24
US8071103B2 (en) 2011-12-06
WO2008011446A3 (en) 2008-09-18
AR061930A1 (es) 2008-10-01
ZA200901132B (en) 2010-10-27
EP2049567A2 (en) 2009-04-22
MX2009000748A (es) 2009-03-31
WO2008011446A2 (en) 2008-01-24
US20090325873A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
CR10619A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR8706A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos, usos
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
CR9266A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos
BRPI0614464A2 (pt) preparação cosmética
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
GB0505942D0 (en) Human to mobile interfaces
DK2051606T3 (da) Lænestol
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
ITRM20060367A1 (it) Muteine del hngf usi terapeutici e composizioni farmaceutiche
FR2896414B1 (fr) Composition cosmetique matifiante
DK2310383T3 (da) 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf
BRPI0814658A2 (pt) Composição farmacêutica líquida estável
IL193117A0 (en) Polypeptide antagonists to cc-chemokine, their preparation and use
NO20065018A (no) Stol
ES1062273Y (es) Butaca perfeccionada
FR2899584B1 (fr) Composition cosmetique antirides
FR2897776B1 (fr) Composition cosmetique anti-age
DOP2007000004A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
FR2899582B1 (fr) Composition cosmetique antirides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)